Objective: To investigate the effect of Imrecoxib applied alone and combined with Xianlinggubao capsule for the treatment of early and middle stage KOA through a comprehensive comparison of the relief of patients symptoms, the functional improvement of knee joint after treatment, providing a new method for the prevention and treatment of KOA in clinical. Methods: Collecting the treated cases of KOA as the research objects from June 2015 to May 2016 in outpatient of Guanghua hospital and Tongren hospital, 126 patients of KOA were included in research, according to the principle of voluntary patients were divided into Imrecoxib group and combination group, then done a study of clinical comparative test. Using SPSS17.0 statistical software processed all data and got the objective results and conclusions through analysis. Results: In the study, a total of 19 cases dropped, 126 patients of KOA got into the result analysis finally. In terms of WOMAC rating scale, after the treatment of 2^nd, 4^th and 8^th week, the difference of standard index between two groups was statistically significant(P<0.05). Conclusions: Imrecoxib is a comparatively ideal non-steroidal anti-inflammatory drug for the treatment of early and middle stage KOA, and the efficiency is reliable. Xianlinggubao capsule can be used as adjuvant therapy in the treatment of early and middle stage KOA, it has no obvious toxic side effect. Combined application of traditional Chinese medicine and Western medicine has less adverse reactions, can effectively relieve the clinical symptoms of KOA, improve the function of knee joint and enhance the quality of life.